Tags : Clinical Trial Collaboration


BMS Signs a Clinical Trial Collaboration with UbiVac to Evaluate

Shots: The two companies collaborated to evaluate the safety, tolerability, and preliminary efficacy of UbiVac’s DPV-00 in combination with BMS’ anti-OX40 (BMS-986178) combined with Opdivo (nivolumab) The P-Ib study will test the hypothesis that combination immunotherapy with the DPV-001 vaccine and anti-OX40 will boost anticancer immunity in patients with advanced TNBC UbiVac’s DRibble Platform Vaccine, […]Read More